Up Therapeutics LLC
Elkridge, MD · Biotech · Private
Small molecule RPN13 proteasome inhibitor (Up284) for glioblastoma and solid tumors
- Grants
- $3.5M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Developing a RPN13 inhibitor for the treatment of Quadruple Negative Breast Cancer | $253,516 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing a RPN13 inhibitor for the treatment of Quadruple Negative Breast Cancer | $308,516 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing a RPN13 inhibitor for the treatment of Quadruple Negative Breast Cancer | $55,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of small molecule RPN13 inhibitors for Treatment of Glioblastoma | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of small molecule RPN13 inhibitors for Treatment of Glioblastoma | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients | $868,417 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients | $1,178,998 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1467 | Endogenex, Inc. | — | $122M |
| 1468 | Nob Hill Therapeutics, Inc. | — | $2.2M |
| 1469 | Aptevo Therapeutics Inc. | — | $5.6M |
| 1470 | Up Therapeutics LLC | — | — |
| 1471 | CALIFORNIA STEM CELL INC | — | $1.9M |
| 1472 | Aptorum Group Ltd | — | $1.6M |
| 1473 | RESBIOTIC, INC. | — | $1.6M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.